Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

Patented cover for stethoscopes will curb hospital-acquired infections

Saints Medical Center is pleased to announce that Richard H. Ma, M.D, chair of its hospitalist department, has received a patent for a lightweight plastic cover for stethoscopes that will dramatically reduce hospital-acquired infections.

9 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

Beginner's guide to cancer

An academic from The University of Nottingham has written the first introductory guide to cancer, covering everything from the biology of the disease and why some people are more at risk of developing it than others, to the latest research into prevention, treatment and cure.

4 Nov 2010

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

FDA new approvals, antibiotic and neurological drugs

Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.

31 Oct 2010

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Forest Laboratories, Inc. announced today that Teflaro(ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin with activity against both gram-positive and gram-negative microorganisms, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired bacterial pneumonia (CABP), including cases caused by Streptococcus pneumoniae bacteremia, and acute bacterial skin and skin structure infection (ABSSSI), including cases caused by methicillin-resistant Staphylococcus aureus (MRSA).

30 Oct 2010

Research Roundup: Primary care doc pay and satisfaction; fixes to Medicare reimbursements; free vaccines?

A critical element of improving population health in underserved areas is the adequacy and distribution of the primary care physician supply, write the authors of this study, who interviewed 42 primary care physicians from both underserved and non-underserved areas in Los Angeles County, California.

30 Oct 2010

Teflaro receives FDA approval for treatment of bacterial infections

The U.S. Food and Drug Administration today approved Teflaro (ceftaroline fosamil), an injectable antibiotic to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA).

30 Oct 2010

Viropharma 2010 third quarter net sales increases 46% to $317.4 million

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2010.

27 Oct 2010

PURE Bioscience raises $2.376M through unregistered private placement

PURE Bioscience, creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that it has sold $2.376 million of its common stock in an unregistered private placement solely to non-affiliated accredited investors.

26 Oct 2010

Knowledge gaps and unjustified fear common among caregivers of children with MRSA

Knowledge gaps and fear - some of it unjustified - are common among the caregivers of children with a drug-resistant staph bacterium known as MRSA, according to the results of a small study from the Johns Hopkins Children Center. These caregivers thirst for timely, detailed and simple information, the researchers add.

26 Oct 2010

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

ViroPharma Incorporated today announced that it has completed enrollment in its Phase 2 study evaluating subcutaneous delivery of Cinryze™ (C1esterase inhibitor [human]). This multi-center, open-label, multi-dose Phase 2 study is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze in adolescent and adult subjects with hereditary angioedema (HAE).

25 Oct 2010

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.

25 Oct 2010

New synthetic population can help computational modelers to study infectious diseases

To help computational modelers who study the spread of infectious diseases, including flu, researchers supported by the National Institutes of Health at RTI International in North Carolina created a synthetic population mirroring U.S. demographics. Now they've added another layer of realism: where the virtual citizens live.

25 Oct 2010

New disease map resource can reduce MRSA infection in hospitalized patients

Gary A. Puckrein, Ph.D., CEO of the National Minority Quality Forum, and Gary Doern, Ph.D., nationally recognized infectious disease expert, will host the launch of the national MRSA Atlas by way of a webinar.

25 Oct 2010

FDA issues complete response letter for ViroPharma's Cinryze

ViroPharma Incorporated today announced the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding Cinryze (C1 Esterase Inhibitor [Human]) industrial scale manufacturing expansion activities. The FDA has requested additional information related to observations from the pre-approval inspection and review of the technical processes.

25 Oct 2010

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate compared with vancomycin for the primary endpoint. The ZEPHyR (Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to methicillin-resistant Staphylococcus aureus) study was the largest ever conducted in this population.

21 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

Detect-Ready MRSA assay receives first independent validation

Molecular Detection Inc. a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that its Detect-Ready MRSA assay has received its first independent validation in a study conducted at St. George's Healthcare NHS Trust, a leading teaching hospital in the UK.

13 Oct 2010

Staphylococcus aureus News and Research

Further Reading

Patented cover for stethoscopes will curb hospital-acquired infections

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Beginner's guide to cancer

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

PolyMedix receives $488,958 grants under QTDP program

FDA new approvals, antibiotic and neurological drugs

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Research Roundup: Primary care doc pay and satisfaction; fixes to Medicare reimbursements; free vaccines?

Teflaro receives FDA approval for treatment of bacterial infections

Viropharma 2010 third quarter net sales increases 46% to $317.4 million

PURE Bioscience raises $2.376M through unregistered private placement

Knowledge gaps and unjustified fear common among caregivers of children with MRSA

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

New synthetic population can help computational modelers to study infectious diseases

New disease map resource can reduce MRSA infection in hospitalized patients

FDA issues complete response letter for ViroPharma's Cinryze

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

Detect-Ready MRSA assay receives first independent validation

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News